Baricitinib for blood clotting in rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests whether baricitinib, a pill that lowers inflammation, can also help reduce blood-clotting risk in people with rheumatoid arthritis. It may help if your arthritis is still active despite current treatment, and you have no other major health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with rheumatoid arthritis.
- Your arthritis is still active even though you are taking standard medications.
- You do not have other autoimmune diseases (like lupus or psoriatic arthritis).
- You do not have diabetes, kidney disease, liver disease, or chronic lung disease.
- You have not had a blood clot or used blood thinners in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
This trial checks how the medication baricitinib affects nerves in people with rheumatoid arthritis. It uses a nerve test to see if the drug causes nerve problems.
This study tests whether adding the drug baricitinib to standard clot-removal treatment for a certain type of stroke improves recovery. It aims to see if the drug reduces inflammation in the brain and leads to better outcomes.
This trial tests whether adding a drug called baricitinib to your usual TPO-RA treatment works better than TPO-RA alone for people with ITP who haven't responded enough to TPO-RA. It aims to see if the combination helps raise platelet counts and reduce bleeding risk.
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.